natgillin/translations-raw huggingface dataset:
Almost all patients had received treatment with AZA or 6-MP concomitantly with or immediately prior to a TNF-blocker.
Skoraj vsi bolniki so bili zdravljeni z AZA ali 6-MP, bodisi sočasno z zaviralcem TNF ali neposredno pred uporabo zaviralca TNF.
• It is very important that you tell your doctor if you have ever had TB, or if you have been in close contact with someone who has had TB.
• Zelo pomembno je, da zdravniku poveste, če ste kdaj imeli tuberkulozo ali če ste bili v tesnem stiku s tuberkuloznim bolnikom.
Efficacy and safety were assessed in two multicenter, double-blind, placebo-controlled studies in patients with active psoriatic arthritis.
Učinkovitost in varnost zdravila so ocenjevali v dveh multicentričnih, dvojno slepih in s placebom kontroliranih študijah pri bolnikih z aktivnim psoriatičnim artritisom.
• Do not use this medicine if it is discoloured or if there are particles present.
• Ne uporabljajte tega zdravila, če opazite, da je raztopina spremenila barvo ali če vsebuje delce.
Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted.
Dovoljeni so bili sočasni stalni odmerki peroralnih aminosalicilatov, kortikosteroidov in/ali imunomodulatorjev.
• Convulsions, nerve problems
• epileptični krči, težave z živčevjem
Median follow-up is based on patients treated.
Mediana dolžine spremljanja bolnikov je bila določena samo z upoštevanjem zdravljenih bolnikov.
If jaundice and/or ALT elevations ≥ 5 times the upper limit of normal develop(s), Remicade should be discontinued, and a thorough investigation of the abnormality should be undertaken.
Če se pojavi zlatenica in/ali zvišanje vrednosti ALT ≥ 5-kratno zgornjo mejo normale, prenehajte z uporabo zdravila Remicade in temeljito raziščite vzroke za nenormalne izvide.
While the numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events, there were higher proportions of patients with serious adverse events and discontinuation due to adverse events in the younger age group than in the older age group.
Število bolnikov v vsaki podskupini je sicer premajhno, da bi dopuščalo dokončne sklepe o vplivu starosti na varnost zdravljenja, vendar pa sta bila deleža bolnikov z resnimi neželenimi učinki in s prekinitvijo zdravljenja zaradi neželenih učinkov v mlajši starostni skupini večja kot v starejši.
Corticosteroid tapering was permitted after week 6.
Zmanjševanje odmerka kortikosteroida je bilo dovoljeno po 6. tednu.
• Possible signs of cancer including but not limited to swelling of lymph nodes, weight loss, fever, unusual skin nodules, changes in moles or skin colouring, or unusual vaginal bleeding.
• možni znaki raka, vključno z, vendar ne omejeno na otekanje bezgavk, izgubo telesne mase, zvišano telesno temperaturo, nenavadnimi kožnimi vozliči, spremembami znamenj ali barve kože, ali nenavadne vaginalne krvavitve.
If you forget or miss an appointment to receive Remicade, make another appointment as soon as possible.
Če ste pozabili ali izpustili odmerek zdravila Remicade Če ste pozabili ali izpustili dogovorjen termin, da bi prejeli zdravilo Remicade, se čim prej dogovorite za naslednjega.
In the 3 mg/kg Remicade group, 4 out of 60 patients had a serious infusion reaction and 3 patients reported a possible anaphylactic reaction (2 of which were among the serious infusion reactions).
V skupini, ki je zdravilo Remicade prejemala v odmerku 3 mg/kg, so imeli 4 od 60-tih bolnikov resno z infuzijo povezano reakcijo, pri 3 pa so poročali o možni anafilaktični reakciji (od tega sta 2 sodili med resne z infuzijo povezane reakcije).
In these patient populations, a reduction in the rate of the progression of joint damage, as measured by X-ray, has been demonstrated (see section 5.1).
V teh populacijah bolnikov so pokazali zmanjšanje hitrosti napredovanja okvare sklepov, ki so jo ugotavljali z rentgenskim slikanjem (glejte poglavje 5.1).
Therefore, the combination of Remicade and anakinra is not recommended.
Kombiniranje zdravila Remicade in anakinre torej ni priporočljivo.
• Patients with COPD and patients who are heavy smokers may have a higher risk of developing cancer with Remicade treatment.
• Bolniki s KOPB in tisti, ki veliko kadijo, imajo lahko povečano tveganje za nastanek raka pri zdravljenju z zdravilom Remicade.
At week 24, all placebo-treated patients crossed over to infliximab induction.
V 24. tednu so vsi s placebom zdravljeni bolniki prešli na uvajanje infliksimaba.
If these medicines do not work well enough, you will be given Remicade which you will take in combination with another medicine called methotrexate to:
Če ta zdravila ne delujejo dovolj dobro, boste prejeli zdravilo Remicade skupaj z zdravilom, imenovanim metotreksat, za:
During Remicade treatment, other concomitant therapies, e.g., corticosteroids and immunosuppressants should be optimised.
Med zdravljenjem z zdravilom Remicade je treba optimizirati druge sočasne terapije, npr. s kortikosteroidi in zdravili za zaviranje imunske odzivnosti.
• A type of blood cancer (lymphoma)
• vrsta krvnega raka (limfom)
Due to its inhibition of TNF, infliximab administered during pregnancy could affect normal immune responses in the newborn.
Ker infliksimab zavira TNF, lahko pri uporabi v času nosečnosti vpliva na normalni imunski odziv novorojenčka.
Powder for concentrate for solution for infusion 1 vial 100 mg
prašek za koncentrat za raztopino za infundiranje 1 viala 100 mg
If a patient has an inadequate response or loses response after this period, consideration may be given to increase the dose step-wise by approximately 1.5 mg/kg, up to a maximum of 7.5 mg/kg every 8 weeks.
Če se bolnik nezadostno odzove na zdravilo ali če pri njem odziv pozneje izgine, mu lahko tudi postopoma povečujete odmerek za približno 1,5 mg/kg na vsakih 8 tednov, do največ 7,5 mg/kg.
Use of TNF-blocking agents, including infliximab, has been associated with cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, including Guillain-Barré syndrome.
Uporaba zaviralcev TNF vključno z infliksimabom je bila povezana s primeri novega pojava oz. poslabšanja kliničnih simptomov in/ali z rentgenskimi znaki demielinizirajoče bolezni osrednjega živčevja, vključno z multiplo sklerozo, in demielinizirajoče bolezni perifernega živčevja, vključno z Guillain-Barréjevim sindromom.
In REACH, 17.5% of randomised patients experienced 1 or more infusion reactions.
V preskušanju REACH se je pri 17,5 % naključno razvrščenih bolnikov pojavila ena oziroma več z infuzijo povezanih reakcij.
Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N = 60), Crohn's disease (N = 112), juvenile rheumatoid arthritis (N = 117) and Kawasaki disease (N = 16) with an overall age range from 2 months to 17 years indicated that exposure to infliximab was dependent on body weight in a non-linear way.
Analiza populacijske farmakokinetike na podlagi podatkov, pridobljenih pri bolnikih z ulceroznim kolitisom (n = 60), Crohnovo boleznijo (N = 112), juvenilnim revmatoidnim artritisom (N = 117) in boleznijo Kawasaki (N = 16) v starostni skupini od 2 mesecev do 17 let, je pokazala, da je izpostavljenost infliksimabu nelinearno odvisna od telesne mase.
Cases of TB have been reported in patients treated with Remicade, even in patients who have already been treated with medicines for TB.
Pri bolnikih, zdravljenih z zdravilom Remicade, so poročali o primerih tuberkuloze, tudi pri bolnikih, ki so že bili zdravljeni z zdravili proti TBC.
In responding patients, the alternative strategies for continued treatment are:
Pri bolnikih, ki so se odzvali na zdravilo, so druge možnosti nadaljnjega zdravljenja naslednje:
Placebo patients received methotrexate while infliximab patients received both infliximab and methotrexate.
Bolniki iz placebo skupine so prejemali metotreksat, medtem ko so bolniki iz infliksimabove skupine prejemali tako infliksimab kot metotreksat.
At 38 weeks, 9 of 101 patients treated with Remicade (2 at 5 mg/kg and 7 at 10 mg/kg) died compared to one death among the 49 patients on placebo.
Po 38 tednih je umrlo 9 od 101 bolnikov, zdravljenih z zdravilom Remicade (2 z odmerkom 5 mg/kg in 7 z odmerkom 10 mg/kg), v primerjavi z eno smrtjo pri 49 bolnikih, ki so prejemali placebo.
AZA was given at a dose of 2.5 mg/kg daily.
AZA so bolniki prejemali v odmerku 2,5 mg/kg na dan.
14 weeks
14 tednov
• Infection of the skin due to a fungus
• okužba kože zaradi glivic
In the 6 mg/kg group, 2 out of 57 patients had a serious infusion reaction, one of whom had a possible anaphylactic reaction (see section 4.4).
V skupini, ki je zdravilo prejemala v odmerku 6 mg/kg, pa sta imela 2 od 57-tih bolnikov resno z infuzijo povezano reakcijo in eden od njiju je morda imel anafilaktično reakcijo (glejte poglavje 4.4).
• This medicine can also be stored in the original carton outside of refrigerated storage up to a maximum of 25 °C for a single period of up to six months, but not beyond the original expiry date.
• To zdravilo se lahko shranjuje tudi v originalni škatli izven hladilnika do največ 25 °C za enkratno obdobje do 6 mesecev, vendar ne dlje od originalnega datuma izteka roka uporabnosti.
• Some patients treated with infliximab have developed certain kinds of skin cancer.
• Pri nekaterih bolnikih, zdravljenih z infliksimabom, so se pojavile določene vrste kožnega raka.
Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects).
Analiza se nanaša na preiskovance, ki so imeli psoriazo nohtov na začetku študije (81,8 % preiskovancev).
• Immune disorders that could affect the lungs, skin and lymph nodes (such as sarcoidosis).
• imunske bolezni, ki lahko prizadenejo pljuča, kožo in bezgavke (na primer sarkoidoza)
In clinical studies, mild or moderate elevations of ALT and AST have been observed in patients receiving Remicade without progression to severe hepatic injury.
V kliničnih preskušanjih so opažali blago ali zmerno zvišanje vrednosti ALT in AST pri bolnikih, ki so prejemali zdravilo Remicade, brez napredovanja motnje do hude jetrne poškodbe.
Cases of tuberculosis, sometimes fatal, including miliary tuberculosis and tuberculosis with extra-pulmonary location have been reported (see section 4.4).
Poročali so tudi o primerih tuberkuloze, včasih celo s smrtnim izidom, vključno z miliarno tuberkulozo in tuberkulozo izven pljuč (glejte poglavje 4.4).
SPIRIT evaluated the efficacy of infliximab induction therapy in 249 patients with plaque psoriasis that had previously received PUVA or systemic therapy.
V študiji SPIRIT so ocenjevali učinkovitost uvodne terapije z infliksimabom pri 249 bolnikih s psoriazo s plaki, ki so pred tem prejemali PUVA ali sistemsko terapijo.
• Reactions at the injection site such as pain, swelling, redness or itching
• reakcije na mestu injiciranja, na primer bolečina, otekanje, pordelost ali srbenje
In clinical studies, delayed hypersensitivity reactions have been uncommon and have occurred after Remicade-free intervals of less than 1 year (see sections 4.4 and 4.8).
V kliničnih študijah so bile pozne preobčutljivostne reakcije občasne in so se pojavile po premoru brez prejemanja zdravila manj kot 1 leto (glejte poglavji 4.4 in 4.8).
In ACT 1 and ACT 2, infliximab improved quality of life, confirmed by statistically significant improvement in both a disease specific measure, IBDQ, and by improvement in the generic 36-item short form survey SF-36.
V študijah ACT 1 in ACT 2 je infliksimab tudi izboljšal kakovost življenja bolnikov, kar je bilo potrjeno s statistično značilnim izboljšanjem rezultata vprašalnika za oceno vnetnih bolezni črevesja IBDQ, ki je specifičen za to bolezen, in z izboljšanjem rezultatov generične kratke ankete SF-36 s 36 postavkami.
• Merkel cell carcinoma (a type of skin cancer)
• karcinom Merklovih celic (vrsta kožnega raka)
In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, antituberculosis therapy should be considered before the initiation of Remicade.
Pri bolnikih, ki imajo več dejavnikov tveganja oziroma pomembne dejavnike tveganja za tuberkulozo in pri katerih je bil test na latentno tuberkulozo negativen, premislite, ali bi bilo treba pri njih pred uvedbo zdravila Remicade najprej zdraviti tuberkulozo.
• Infection due to a live vaccine because of a weakened immune system.
• okužba zaradi živega cepiva zaradi oslabljenega imunskega sistema
If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with Remicade and is positive for antibodies against double-stranded DNA, further treatment with Remicade must not be given (see section 4.8).
Če se po zdravljenju z zdravilom Remicade pri bolniku pojavijo simptomi, ki kažejo na lupusu podoben sindrom, in je bolnik pozitiven na protitelesa proti dvojnoverižni DNA, ne sme več prejeti tega zdravila (glejte poglavje 4.8).
At 102 weeks there were 80 subjects still on infliximab treatment and among those, 71 (89%) were ASAS 20 responders.
Čez 102 tedna se je z infliksimabom še vedno zdravilo 80 preiskovancev in od tega jih je imelo kar 71 (89 %) odziv ASAS 20.
• Some patients receiving Remicade have developed serious liver problems.
• Pri nekaterih bolnikih, ki prejemajo zdravilo Remicade, so se pojavile resne težave z jetri.
Long-term studies have not been performed to evaluate the carcinogenic potential of infliximab.
Dolgoročne študije za ovrednotenje kancerogenosti infliksimaba niso bile izvedene.
• Tell your doctor before you are given Remicade if you are a carrier of hepatitis B or have ever had it.
• Preden prejmete zdravilo Remicade, povejte zdravniku, če ste prenašalec hepatitisa B ali če ste ga imeli kdaj v preteklosti.
• Tell your doctor if you think you might be at risk of contracting hepatitis B.
• Povejte zdravniku, če mislite, da pri vas obstaja možnost, da bi se okužili s hepatitisom B.
Higher degrees of clinical response (ACR50 and ACR70) were observed in all infliximab groups at 30 and 54 weeks compared with methotrexate alone.
Izrazitejši klinični odziv (ACR 50 in ACR 70) so v 30. in 54. tednu opažali v vseh skupinah, ki so prejemale infliksimab, v primerjavi z bolniki, ki so prejemali le metotreksat.
Week 54 Clinical Response
54. teden Klinični odziv
control = All patients had active RA despite treatment with stable methotrexate doses for 6 months prior to enrolment and were to remain on stable doses throughout the study.
Kontrolna skupina: Vsi bolniki so imeli aktivni revmatoidni artritis kljub zdravljenju s stalnimi odmerki metotreksata že 6 mesecev pred vključitvijo v študijo; te odmerke so prejemali še naprej ves čas študije.
Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology.
Infliksimab je himerno človeško-glodalsko monoklonsko protitelo IgG1, pridobljeno iz celic glodalskega hibridoma s tehnologijo rekombinantne DNK.
Ask your doctor to record the type and date of last screening(s) for tuberculosis (TB) below: Test
Zdravnik naj zabeleži tip in datum zadnjega presejalnega(ih) testa(ov) za tuberkulozo (TBC):
All patients were required to be on a stable dose of 6-MP, AZA or MTX (35% were also receiving corticosteroids at baseline).
Vsi bolniki so morali prejemati stalen odmerek 6-MP, AZA ali MTX (35 % jih je na začetku prejemalo tudi kortikosteroide).
• Inflammation of the lining of the brain (meningitis)
• vnetje možganskih ovojnic (meningitis)
Lung disease or heavy smoking
Pljučna bolezen ali bolniki, ki veliko kadijo
The combination of Remicade and abatacept is not recommended.
Kombiniranje zdravila Remicade in abatacepta torej ni priporočljivo.
Infliximab-treated patients demonstrated significant improvement in physical function as assessed by HAQ.
Pri bolnikih, zdravljenih z infliksimabom, so ugotovili bistveno izboljšanje funkcije sklepov, kar so ocenjevali z vprašalnikom HAQ.
• Circulation problems such as low or high blood pressure
• težave s krvnim obtokom, na primer nizek ali visok krvni tlak
Invasive fungal infections
Invazivne glivične okužbe
Remicade has been studied only in combination with conventional immunosuppressive therapy.
Zdravilo so preučevali le v kombinaciji z običajno imunosupresivno terapijo.
• The active substance is infliximab.
• Učinkovina je infliksimab.
Remicade treatment is to be initiated and supervised by qualified physicians experienced in the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis or psoriasis.
Zdravljenje z zdravilom Remicade mora uvesti in nadzorovati kvalificiran zdravnik, ki je izkušen v diagnostiki in zdravljenju revmatoidnega artritisa, vnetnih bolezni črevesa, ankilozirajočega spondilitisa, psoriatičnega artritisa ali psoriaze.
Due to methodological limitations, a negative assay did not exclude the presence of antibodies to infliximab.
Zaradi pomanjkljivosti uporabljene metode pa negativen izvid ni izključil možnosti za prisotnost protiteles proti infliksimabu.
Significant improvements in health-related quality of life were also demonstrated as measured by the physical and mental component summary scores of the SF-36 in IMPACT 2.
Ugotovili so tudi bistveno izboljšanje kakovosti življenja v zvezi z zdravjem, kar so merili na podlagi delnih ocen, to je seštevkov za telesne in duševne komponente SF-36 v študiji IMPACT 2.
• Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur followed by infusions of 5 mg/kg every 8 weeks (see ‘Re-administration' below and section 4.4).
• Ponovna uporaba zdravila: Infuzija v odmerku 5 mg/kg, če se ponovijo znaki in simptomi bolezni, čemur naj sledijo infuzije v odmerku 5 mg/kg na vsakih 8 tednov (glejte poglavje “Ponovna uporaba zdravila” spodaj in poglavje 4.4).
The volume of distribution at steady state (median Vd of 3.0 to 4.1 litres) was not dependent on the administered dose and indicated that infliximab is predominantly distributed within the vascular compartment.
(mediana Vd od 3,0 do 4,1 litra) ni bil odvisen od danega odmerka, kar pomeni, da se infliksimab razporedi pretežno po žilnem razdelku.
Heart problems
Težave s srcem
As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much.
Če ste prejeli prevelik odmerek zdravila Remicade Ker boste zdravilo prejeli od zdravnika ali medicinske sestre, je zelo malo verjetno, da ga boste prejeli preveč.
Structural joint damage (erosions and joint space narrowing) in both hands and feet was measured by the change from baseline in the total van der Heijde-modified Sharp score (0-440).
Strukturne okvare sklepov (erozije in zožitev sklepne špranje) tako na rokah kot na stopalih so merili na podlagi spremembe skupnega rezultata po metodi van der Heijde, modificirani po Sharpu (0 - 440) glede na začetne vrednosti.
Caution should also be exercised in patients with psoriasis and a medical history of extensive immunosuppressant therapy or prolonged PUVA treatment.
Previdnost je potrebna tudi pri bolnikih s psoriazo in obsežno imunosupresivno terapijo ali daljšim zdravljenjem s PUVA v anamnezi.
In Crohn's disease, experience with re-administration if signs and symptoms of disease recur is limited and comparative data on the benefit/risk of the alternative strategies for continued treatment are lacking.
Pri Crohnovi bolezni je malo izkušenj s ponovnim dajanjem zdravila po ponovitvi znakov in simptomov bolezni, primerjalnih podatkov o razmerju med koristmi in tveganji drugih možnosti nadaljnjega zdravljenja pa ni.
Care should be taken and patients should continue to be monitored when switching from one biologic to another, since overlapping biological activity may further increase the risk for adverse reactions, including infection.
Prehod na zdravljenje z drugim biološkim zdravilom tipa DMARD Pri prehodu z enega biološkega zdravila na drugega je potrebna previdnost, bolnike pa je treba še naprej spremljati, ker se zaradi prekrivanja biološke učinkovitosti lahko še poveča tveganje za neželene učinke, vključno z okužbami.
• Low blood counts, including a severely decreased number of white blood cells
• nizko število krvnih celic, vključno z močnim znižanjem števila belih kvnih celic
Because of the nature of the adverse reactions seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNF-blocking agents.
Glede na vrsto neželenih učinkov, ki so jih opažali pri kombinirani terapiji z etanerceptom in anakinro, lahko podobni toksični učinki nastopijo tudi kot posledica kombiniranja anakinre in drugih zaviralcev TNF.
• Blood problems such as anaemia or low white blood cell count
• težave s krvjo kot na primer anemija ali nizko število belih krvnih celic
In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of Remicade (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1 hour.
Skrajšane infuzije pri indikacijah za odrasle bolnike Pri skrbno izbranih odraslih bolnikih, ki so dobro prenesli vsaj 3 začetne 2-urne infuzije zdravila Remicade (uvajalna faza zdravljenja) in so trenutno na vzdrževalnem zdravljenju, lahko razmislite o skrajšanju naslednjih infuzij, vendar ne na manj kot 1 uro.
Significant improvements from baseline were demonstrated in DLQI (p < 0.001) and the physical and mental component scores of the SF 36 (p < 0.001 for each component comparison).
Pri oceni po DLQI (p < 0,001) so dokazali bistveno izboljšanje glede na začetne vrednosti, pa tudi glede ocen telesne in duševne komponente po SF 36 (p < 0,001 za primerjavo vsake komponente).
Of these 108 patients, 27 were treated with the recommended dosage of infliximab 5 mg/kg.
27 od teh 108 bolnikov so zdravili s priporočenim odmerkom infliksimaba, 5 mg/kg.
After infliximab treatment, patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP), and increased haemoglobin levels in rheumatoid arthritis patients with reduced haemoglobin levels, compared with baseline.
Po zdravljenju z infliksimabom se je pri bolnikih zmanjšala serumska koncentracija interlevkina 6 (IL-6) in C-reaktivnega proteina (CRP) in zviša nivo hemoglobina pri bolnikih z revmatoidnim artritisom, ki imajo ta nivo sicer znižan, v primerjavi z izhodiščno vrednostjo.
Upon removal from refrigerated storage, Remicade must not be returned to refrigerated storage.
Ko zdravilo Remicade enkrat vzamete iz hladilnika, ga ne smete vrniti nazaj v hladilnik.
The efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies: SPIRIT and EXPRESS.
Učinkovitost infliksimaba so ocenjevali v dveh multicentričnih, randomiziranih, dvojno slepih študijah: SPIRIT in EXPRESS.
• Small red or purple spots caused by bleeding under the skin
• majhne rdeče ali vijolične pike zaradi podkožnih krvavitev
Warnings and precautions Talk to your doctor before or during treatment with Remicade if you have:
Opozorila in previdnostni ukrepi Pred ali med zdravljenjem z zdravilom Remicade se v naslednjih primerih posvetujte z zdravnikom:
In psoriatic arthritis, short term treatment with Remicade reduced the number of T-cells and blood vessels in the synovium and psoriatic skin.
Pri psoriatičnem artritisu je kratkotrajno zdravljenje z zdravilom Remicade zmanjšalo število celic T in krvnih žil v sinovialni ovojnici in v psoriatično spremenjeni koži.
Week 10
10. teden
Isolated cases of liver failure resulting in liver transplantation or death have occurred.
V osamljenih primerih je prišlo do odpovedi jeter, ki je zahtevala transplantacijo jeter ali povzročila smrt.
Cases of transient visual loss occurring during or within 2 hours of Remicade infusion have been reported.
Poročali so o primerih prehodne izgube vida, ki je nastopila med infundiranjem ali v roku 2 ur po prejemu infuzije zdravila Remicade.